Banerjee S - Search Results

1

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Ang JE, et al. Among authors: banerjee s. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. Clin Cancer Res. 2013. PMID: 23922302

2

Mechanisms of disease: angiogenesis and the management of breast cancer.

Banerjee S, Dowsett M, Ashworth A, Martin LA. Banerjee S, et al. Nat Clin Pract Oncol. 2007 Sep;4(9):536-50. doi: 10.1038/ncponc0905. Nat Clin Pract Oncol. 2007. PMID: 17728712 Review.

3

The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.

Banerjee S, Pancholi S, A'hern R, Ghazoui Z, Smith IE, Dowsett M, Martin LA. Banerjee S, et al. Clin Cancer Res. 2008 May 1;14(9):2656-63. doi: 10.1158/1078-0432.CCR-07-1352. Clin Cancer Res. 2008. PMID: 18451229 Clinical Trial.

4

The future of targeted therapies in ovarian cancer.

Banerjee S, Gore M. Banerjee S, et al. Oncologist. 2009 Jul;14(7):706-16. doi: 10.1634/theoncologist.2009-0013. Epub 2009 Jul 10. Oncologist. 2009. PMID: 19592450 Free article. Review.

5

Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.

Banerjee S, Cunningham D. Banerjee S, et al. Clin Colorectal Cancer. 2010 Jun;9 Suppl 1:S28-35. doi: 10.3816/CCC.2010.s.004. Clin Colorectal Cancer. 2010. PMID: 20630848 Review.

6

Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.

Banerjee S, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, Martin LA. Banerjee S, et al. Clin Cancer Res. 2010 Aug 15;16(16):4178-87. doi: 10.1158/1078-0432.CCR-10-0456. Epub 2010 Aug 3. Clin Cancer Res. 2010. PMID: 20682704 Free article.

7

Making the best of PARP inhibitors in ovarian cancer.

Banerjee S, Kaye SB, Ashworth A. Banerjee S, et al. Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10. Nat Rev Clin Oncol. 2010. PMID: 20700108 Review.

8

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Banerjee S, Kaye S. Banerjee S, et al. Curr Oncol Rep. 2011 Dec;13(6):442-9. doi: 10.1007/s11912-011-0193-9. Curr Oncol Rep. 2011. PMID: 21913063 Review.

9

The role of targeted therapy in ovarian cancer.

Banerjee S, Kaye S. Banerjee S, et al. Eur J Cancer. 2011 Sep;47 Suppl 3:S116-30. doi: 10.1016/S0959-8049(11)70155-1. Eur J Cancer. 2011. PMID: 21943965 Review.

10

Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Banerjee S, Kaye SB. Banerjee S, et al. Nat Rev Clin Oncol. 2012 Feb 28;9(4):194-6. doi: 10.1038/nrclinonc.2012.28. Nat Rev Clin Oncol. 2012. PMID: 22371131 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,230 results

Search Page

Filters